Characteristics of patients and pathological characteristics of MR/US biopsy proven cancers

No. pts/No. lesions	81/88*
Median age (range)	64	(46—83)
Median ng/ml PSA (range)	7.4	(2.2—25.0)
Median ml pathological prostate vol (range)	44.8 (18.0—137.0)
No. clinical stage (%):
cT1c	67	(82.7)
cT2a—c	14	(17.3)
No. pathological stage (%):
pT2a, b	11	(13.6)
pT2c	49	(60.5)
pT3a	17	(21.0)
pT3b	4	(4.9)
No. Gleason score (%):
3 + 3	21	(23.9)
3 + 4	48	(54.5)
4 + 3	9	(10.2)
4 + 4	2	(2.3)
3 + 5	4	(4.5)
4 + 5	4	(4.5)
No. Ca location (%):
Peripheral zone	65	(73.9)
Transition zone	23	(26.1)
PCV (ml):
Median (range)	0.75 (0.01—8.97)
No. less than 0.2 (%)	22	(25.0)
No. 0.2—less than 0.5 (%)	12	(13.6)
No. 0.5—less than 2.0 (%)	37	(42.0)
No. 2.0 or greater (%)	17	(19.3)
Median ml MCV (range)	0.5	(0.06—6.20)

^*Seven patients each had 2 MR/US fusion targeted biopsy proven lesions.